You are here: Industry Insights > Doptelet

News List

First Patient Dosed in Avatrombopag Study ITP in Children americanpharmaceuticalreview
March 22, 2021
Swedish Orphan Biovitrum announced the first patient has been dosed with avatrombopag, a thrombopoietin receptor agonist (TPO-RA), for treatment of immune thrombocytopenia (ITP) in pediatric patients.
Sobi launches thrombocytopenia drug Doptelet in EU pharmatimes
November 06, 2020
Sobi (Swedish Orphan Biovitrum) has launched Doptelet (avatrombopag) in Europe, which is approved for the treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD).
NICE pushes Doptelet for pre-surgery liver disease treatment PharmaTimes
March 05, 2020
The National Institute for Health and Care Excellence (NICE) has published a new final draft guidance recommending Dova Pharmaceuticals’ Doptelet (avatrombopag) for thrombocytopenia - ...
Can tiny Dova take on Novartis? With its 2nd Doptelet nod and a price cut, maybe so fiercepharma
July 04, 2019
In what one analyst team called Dova Pharmaceuticals’ “biggest catalyst to date,” the company won a second FDA nod for its platelet-boosting drug Doptelet, setting the stage for direct competition against Novartis and its still-growing blockbuster Promact
Dova Pharmaceuticals Announces FDA Approval of Doptelet (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP) drugs
June 28, 2019
Dova Pharmaceuticals Announces FDA Approval of Doptelet (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP).